Division of Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo.
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colo.
J Allergy Clin Immunol. 2022 Oct;150(4):965-971.e8. doi: 10.1016/j.jaci.2022.02.026. Epub 2022 Mar 15.
Lipid mediators, bioactive products of polyunsaturated fatty acid metabolism, contribute to inflammation initiation and resolution in allergic diseases; however, their presence in lung-related biosamples has not been fully described.
We aimed to quantify lipid mediators in the nasal airway epithelium and characterize preliminary associations with asthma.
Using liquid chromatography-mass spectrometry, we conducted a pilot study to quantify 56 lipid mediators from nasal epithelial samples collected from 11 female participants of an outpatient asthma clinic and community controls (aged 30-55 years). We examined the presence of each compound using descriptive statistics to test whether lipid mediators could distinguish subjects with asthma (n = 8) from control subjects (n = 3) using linear regression and partial least squares discriminant analysis.
Fifteen lipid mediators were detectable in all samples, including resolvin (Rv) D5 (RvD5), with the highest median concentrations (in pg/μg protein) of 13-HODE (126.481), 15-HETE (32.869), and 13-OxoODE (13.251). From linear regression adjusted for age, prostaglandin E (PGE2) had a trend (P < .1) for higher concentrations in patients with severe asthma compared to controls (mean difference, 0.95; 95% confidence interval, -0.04 to 1.95). Asthma patients had higher scores on principal component 3 compared to controls (mean difference, 2.42; 95% confidence interval, 0.89 to 3.96), which represented lower levels of proresolving 15-HEPE, 19,20-DiHDPA, RvD5, 14-HDHA, 17-HDHA, and 13-HOTrE. Most of these compounds were best at discriminating asthma cases from controls in partial least squares discriminant analysis.
Lipid mediators are detectable in the nasal epithelium, and their levels distinguish asthma cases from controls.
脂质介质是多不饱和脂肪酸代谢的生物活性产物，有助于过敏疾病中炎症的启动和消退；然而，它们在与肺部相关的生物样本中的存在尚未得到充分描述。
我们旨在定量分析鼻气道上皮细胞中的脂质介质，并初步分析其与哮喘的关系。
使用液相色谱-质谱法，我们对 11 名门诊哮喘诊所和社区对照（年龄 30-55 岁）女性参与者的鼻上皮样本进行了一项试点研究，以定量分析 56 种脂质介质。我们使用描述性统计检验来检验每种化合物的存在，以使用线性回归和偏最小二乘判别分析来检验脂质介质是否可以区分哮喘患者（n=8）和对照者（n=3）。
所有样本中均检测到 15 种脂质介质，其中包括分辨率最高的（Rv）D5（RvD5），其中位数浓度（以 pg/μg 蛋白计）最高的是 13-HODE（126.481）、15-HETE（32.869）和 13-OxoODE（13.251）。经年龄调整的线性回归分析显示，与对照组相比，重度哮喘患者的前列腺素 E（PGE2）浓度有升高趋势（P<.1）（平均差异，0.95；95%置信区间，-0.04 至 1.95）。与对照组相比，哮喘患者在主成分 3 上的得分更高（平均差异，2.42；95%置信区间，0.89 至 3.96），这代表着更低水平的促消退 15-HEPE、19,20-DiHDPA、RvD5、14-HDHA、17-HDHA 和 13-HOTrE。在偏最小二乘判别分析中，这些化合物大多数在区分哮喘病例和对照组方面表现最佳。
脂质介质可在鼻上皮细胞中检测到，其水平可区分哮喘病例和对照组。
